- Azar II AM. Plenary Address to National Governors Association. HHS.gov. Published February 24, 2018. Accessed June 8, 2022. Available here.
- U.S. Substance Abuse and Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. SAMHSA. Published January 25, 2023. Accessed February 14, 2023. Available here.
- U.S. Department of Justice, Drug Enforcement Administration. Letter from the Office of the Administrator. Released January 12, 2023. Available here.
- U.S. Substance Abuse and Mental Health Services Administration. Naltrexone. U.S. Substance Abuse and Mental Health Services Administration. Published 2022. Accessed June 8, 2022. Available here.
- Mattick RP, Breen C, Kimber J, Davoli M. Methadone Maintenance Therapy Versus No Opioid Replacement Therapy for Opioid Dependence. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2009. Accessed January 30, 2014. Available here.
- Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. Available here.
- National Institutes of Health. Methadone and buprenorphine reduce risk of death after opioid overdose. National Institutes of Health (NIH). Published June 19, 2018. Accessed June 8, 2022. Available here.
- Wakeman SE, Larochelle MR, Ameli O, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open. 2020;3(2):e1920622. Available here.
- Ajazi EM, Dasgupta N, Marshall SW, et al. Revisiting the X: BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis. Journal of Addiction Medicine. Published online December 3, 2021. Available here.
- Cheney, T. Vivitrol and Overdose Risk. Maine Suboxone - Enso Recovery. Published Online February 2022. Accessed June 8, 2022. Available here.
- Alkermes Inc. VIVITROL (naltrexone for extended-release injectable suspension) [package insert]. Published online September 2019. Accessed June 8, 2022. Available here.
- Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-1513. Available here.
- Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-218. Available here.
- Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90-96. Available here.
- Gryczynski J, Schwartz R, O’Grady K, Jaffe J. Treatment entry among individuals on a waiting list for methadone maintenance. Am J Drug Alcohol Abuse. 2009;35(5):290-294. Available here.
- Cernasev A, Hohmeier KC, Frederick K, Jasmin H, Gatwood J. A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder. Explor Res Clin Soc Pharm. 2021;2:100029. Available here.
- Dunphy C, Peterson C, Zhang K, Jones CM. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? Drug Alcohol Depend. 2021;225:108784. Available here.
- Oros SM, Christon LM, Barth KS, Berini CR, Padgett BL, Diaz VA. Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina. Int J Psychiatry Med. 2021;56(1):14-39. doi:10.1177/0091217420946240. Available here.
- Joudrey PJ, Adams ZM, Bach P, et al. Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada. JAMA Network Open. 2021;4(7):e2118223-e2118223. Available here.
- Peles E, Schreiber S, Adelson M. Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry. J Addict Med. 2013;7(3):177-182. Available here.
- Carroll JJ, Rich JD, Green TC. The More Things Change: Buprenorphine/naloxone Diversion Continues While Treatment Remains Inaccessible. Journal of Addiction Medicine. 2018;12(6):459-465. Available here.
- Legal Action Center. Cases Involving Discrimination Based on Treatment with Medication for Opioid Use Disorder (MOUD). Published online June 6, 2022. Accessed June 8, 2022. Available here.
- U.S. Department of Justice. Justice Department Files Suit Against Pennsylvania Court System for Discriminating Against People with Opioid Use Disorder. The United States Department of Justice. Published February 24, 2022. Accessed June 8, 2022. Available here.
- Carroll JJ, Green TC, Noonan RK. Evidence-Based Strategies for Prevention Opioid Overdose: What’s Working in the United States. Published online 2018. Accessed October 10, 2018. Available here.
- Clark SA, Davis C, Wightman RS, et al. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island. J Subst Abuse Treat. 2021;124:108283. Available here.
- El-Sabawi T, Baney M, Canzater SL, Weizman S. The New Mobile Methadone Rules And What They Mean For Treatment Access | Health Affairs Forefront. Health Affairs. Published August 4, 2021. Accessed June 8, 2022. Available here.
- Kawasaki S, Hwang G, Buckner K, et al. Collaborative health systems ECHO: The use of tele-education platform to facilitate communication and collaboration with recipients of state targeted response funds in Pennsylvania. Subst Abus. 2022;43(1):892-900. Available here.
- McClellan C, Moriya A, Simon K. Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017. J Subst Abuse Treat. 2022;132:108645. Available here.
- Gifford K, Walls J, Ranji U, Apr 27 IGP, 2017. Medicaid Coverage of Pregnancy and Perinatal Benefits: Results from a State Survey. KFF. Published April 27, 2017. Accessed June 8, 2022. Available here.
- Winograd RP, Presnall N, Stringfellow E, et al. The case for a medication first approach to the treatment of opioid use disorder. American Journal of Drug & Alcohol Abuse. 2019;45(4):333-340. Available here.
- Brooklyn JR, Sigmon SC. Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact. J Addict Med. 2017;11(4):286-292. Available here.
- Winograd RP, Wood CA, Stringfellow EJ, et al. Implementation and evaluation of Missouri’s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abuse Treat. 2020;108:55-64. Available here.
- Prevention Point Philadelphia. STEP. Prevention Point. Published 2020. Accessed June 8, 2022. Available here.
ARPA Impact Report: An Analysis of How Counties are Addressing National Issues With Local Investments
With American Rescue Plan funds, counties are strengthening America’s workforce, addressing the nation’s behavioral health crisis, expanding broadband access, improving housing affordability and building prosperous communities for the next generation.Learn More